Related Experiment Video

Updated: Jun 16, 2026

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies

Joel Rosenbloom1, Susan V Castro, Sergio A Jimenez

  • 1Jefferson Institute of Molecular Medicine, Thomas Jefferson University, 233 South 10th Street, Room 509, Bluemle Life Science Building, Philadelphia, PA 19107-5541, USA.

Annals of Internal Medicine
|February 4, 2010
PubMed

Insights

Fibrotic diseases involve excessive extracellular matrix deposition. Inhibiting transforming growth factor-beta (TGF-beta) pathways, specifically those activating cellular Abelson (c-Abl) kinase, offers a novel therapeutic strategy for these challenging conditions.

Area of Science:

  • Fibrosis research
  • Molecular biology
  • Drug discovery

Background:

  • Fibrotic diseases are characterized by abnormal extracellular matrix deposition, affecting organs like lungs, liver, and kidneys.
  • These progressive conditions present significant treatment challenges due to limited effective therapies.
  • Transforming growth factor-beta (TGF-beta) plays a central role in fibrotic pathogenesis.

Purpose of the Study:

  • To explore novel therapeutic approaches for fibrotic disorders.
  • To investigate the role of TGF-beta signaling in fibrosis.
  • To identify potential drug targets within the TGF-beta pathway.

Main Methods:

  • Investigated the TGF-beta signaling pathway.
  • Focused on the activation of cellular Abelson (c-Abl) tyrosine kinase.
  • Evaluated the efficacy of c-Abl inhibitors, such as imatinib mesylate.

Main Results:

  • Transforming growth factor-beta (TGF-beta) signaling activates cellular Abelson (c-Abl) kinase.
  • Inhibition of c-Abl kinase diminishes the fibrogenic effects of TGF-beta.
  • This pathway modulation shows potential in reducing fibrotic processes.

Conclusions:

  • Targeting TGF-beta activated pathways, specifically c-Abl, is a promising therapeutic strategy for fibrotic diseases.
  • Basic research into fibrotic pathogenesis enables the development of novel treatments.
  • Agents like imatinib mesylate demonstrate potential in mitigating fibrotic disease effects.

More Related Videos

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies06:46

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies

Published on: February 15, 2019

Related Concept Videos

Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...